Literature DB >> 35124513

Chalcones from Angelica keiskei (ashitaba) inhibit key Zika virus replication proteins.

Melina Mottin1, Lindsay K Caesar2, David Brodsky3, Nathalya C M R Mesquita4, Ketllyn Zagato de Oliveira4, Gabriela Dias Noske3, Bruna K P Sousa5, Paulo R P S Ramos5, Hannah Jarmer3, Bonnie Loh3, Kimberley M Zorn6, Daniel H Foil6, Pedro M Torres7, Rafael V C Guido4, Glaucius Oliva4, Frank Scholle3, Sean Ekins6, Nadja B Cech2, Carolina H Andrade8, Scott M Laster9.   

Abstract

Zika virus (ZIKV) is a dangerous human pathogen and no antiviral drugs have been approved to date. The chalcones are a group of small molecules that are found in a number of different plants, including Angelica keiskei Koidzumi, also known as ashitaba. To examine chalcone anti-ZIKV activity, three chalcones, 4-hydroxyderricin (4HD), xanthoangelol (XA), and xanthoangelol-E (XA-E), were purified from a methanol-ethyl acetate extract from A. keiskei. Molecular and ensemble docking predicted that these chalcones would establish multiple interactions with residues in the catalytic and allosteric sites of ZIKV NS2B-NS3 protease, and in the allosteric site of the NS5 RNA-dependent RNA-polymerase (RdRp). Machine learning models also predicted 4HD, XA and XA-E as potential anti-ZIKV inhibitors. Enzymatic and kinetic assays confirmed chalcone inhibition of the ZIKV NS2B-NS3 protease allosteric site with IC50s from 18 to 50 µM. Activity assays also revealed that XA, but not 4HD or XA-E, inhibited the allosteric site of the RdRp, with an IC50 of 6.9 µM. Finally, we tested these chalcones for their anti-viral activity in vitro with Vero cells. 4HD and XA-E displayed anti-ZIKV activity with EC50 values of 6.6 and 22.0 µM, respectively, while XA displayed relatively weak anti-ZIKV activity with whole cells. With their simple structures and relative ease of modification, the chalcones represent attractive candidates for hit-to-lead optimization in the search of new anti-ZIKV therapeutics.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angelica keiskei; Ashitaba; Chalcones; Polymerase; Protease; Zika virus

Mesh:

Substances:

Year:  2022        PMID: 35124513      PMCID: PMC9187613          DOI: 10.1016/j.bioorg.2022.105649

Source DB:  PubMed          Journal:  Bioorg Chem        ISSN: 0045-2068            Impact factor:   5.307


  73 in total

1.  GROMACS: fast, flexible, and free.

Authors:  David Van Der Spoel; Erik Lindahl; Berk Hess; Gerrit Groenhof; Alan E Mark; Herman J C Berendsen
Journal:  J Comput Chem       Date:  2005-12       Impact factor: 3.376

Review 2.  Proteases from dengue, West Nile and Zika viruses as drug targets.

Authors:  Christoph Nitsche
Journal:  Biophys Rev       Date:  2019-02-26

3.  Purification of Zika virus RNA-dependent RNA polymerase and its use to identify small-molecule Zika inhibitors.

Authors:  Hong-Tao Xu; Said A Hassounah; Susan P Colby-Germinario; Maureen Oliveira; Clare Fogarty; Yudong Quan; Yingshan Han; Olga Golubkov; Ilinca Ibanescu; Bluma Brenner; Brent R Stranix; Mark A Wainberg
Journal:  J Antimicrob Chemother       Date:  2017-03-01       Impact factor: 5.790

4.  Uveitis Associated with Zika Virus Infection.

Authors:  João M Furtado; Danillo L Espósito; Taline M Klein; Tomás Teixeira-Pinto; Benedito A da Fonseca
Journal:  N Engl J Med       Date:  2016-06-22       Impact factor: 91.245

5.  Comparative Protein Structure Modeling Using MODELLER.

Authors:  Benjamin Webb; Andrej Sali
Journal:  Curr Protoc Bioinformatics       Date:  2016-06-20

6.  Target profiling of 4-hydroxyderricin in S. aureus reveals seryl-tRNA synthetase binding and inhibition by covalent modification.

Authors:  Oliver A Battenberg; Yinliang Yang; Steven H L Verhelst; Stephan A Sieber
Journal:  Mol Biosyst       Date:  2013-01-08

7.  The crystal structure of Zika virus NS5 reveals conserved drug targets.

Authors:  Wenqian Duan; Hao Song; Haiyuan Wang; Yan Chai; Chao Su; Jianxun Qi; Yi Shi; George F Gao
Journal:  EMBO J       Date:  2017-03-02       Impact factor: 11.598

8.  High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication.

Authors:  Rafaela S Fernandes; Gabriela D Noske; Victor O Gawriljuk; Ketllyn I Z de Oliveira; Andre S Godoy; Nathalya C M R Mesquita; Glaucius Oliva
Journal:  J Vis Exp       Date:  2021-10-30       Impact factor: 1.355

9.  A conformational switch high-throughput screening assay and allosteric inhibition of the flavivirus NS2B-NS3 protease.

Authors:  Matthew Brecher; Zhong Li; Binbin Liu; Jing Zhang; Cheri A Koetzner; Adham Alifarag; Susan A Jones; Qishan Lin; Laura D Kramer; Hongmin Li
Journal:  PLoS Pathog       Date:  2017-05-25       Impact factor: 7.464

Review 10.  The A-Z of Zika drug discovery.

Authors:  Melina Mottin; Joyce V V B Borba; Rodolpho C Braga; Pedro H M Torres; Matheus C Martini; Jose Luiz Proenca-Modena; Carla C Judice; Fabio T M Costa; Sean Ekins; Alexander L Perryman; Carolina Horta Andrade
Journal:  Drug Discov Today       Date:  2018-06-20       Impact factor: 7.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.